HCV Protease

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1482 Daclatasvir (BMS-790052) <1 mg/mL 148 mg/mL 148 mg/mL
S1538 Telaprevir (VX-950) <1 mg/mL 136 mg/mL <1 mg/mL
S1480 Lomibuvir (VX-222, VCH-222) <1 mg/mL 89 mg/mL 89 mg/mL
S1183 Danoprevir (ITMN-191) <1 mg/mL 144 mg/mL 144 mg/mL
S3728 Grazoprevir <1 mg/mL 100 mg/mL 100 mg/mL
S3733 Boceprevir <1 mg/mL 100 mg/mL 100 mg/mL
S3724 Velpatasvir 100 mg/mL 100 mg/mL 100 mg/mL
S7579 Ledipasvir (GS5885) <1 mg/mL 100 mg/mL 100 mg/mL
Catalog No. Information Product Use Citations Product Validations
S1482

Daclatasvir (BMS-790052)

Daclatasvir (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.

S1538

Telaprevir (VX-950)

Telaprevir (VX-950) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM.

S1480

Lomibuvir (VX-222, VCH-222)

Lomibuvir (VX-222, VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. Phase 2.

S1183

Danoprevir (ITMN-191)

Danoprevir(ITMN-191) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.

S3728New

Grazoprevir

Grazoprevir anhydrous is a Hepatitis C Virus NS3/4A Protease inhibitor with IC50 values of 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively.

S3733New

Boceprevir

Boceprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.

S3724New

Velpatasvir

Velpatasvir is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication.

S7579

Ledipasvir (GS5885)

Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

Tags: HCV protease treatment | HCV protease assay | HCV protease inhibitors review